Xiaoyan Jiang

Dr. Xiaoyan Jiang is a Distinguished Scientist at the Terry Fox Laboratory of the BC Cancer, a Professor in the Department of Medical Genetics and an Associate Member of the Division of Hematology and Experimental Medicine, the Department of Medicine at the University of British Columbia. She is also an Adjunct Professor at the Shanghai Institute of Medical Genetics of the Shanghai Jiao Tong University and Soochow University. Her research focuses on basic and translational research of molecular properties of leukemic stem cells that contribute to the development of leukemia and drug resistance, and she has pioneered local efforts to develop new therapeutic approaches to directly target these critical cells. The Jiang Lab has recently demonstrated that AHI-1 (Abelson helper integration site-1), a scaffolding oncoprotein, is highly deregulated in BCR-ABL+ leukemic stem cells and interacts with multiple kinases and other proteins to enhance leukemia-initiating activity and drug-resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Prof. Jiang’s group has been testing new therapeutic agents/inhibitors and combination treatment strategies that can effectively eradicate drug-resistant CML and acute myeloid leukemia (AML) stem/progenitor cells, by exploring novel oncolytic virotherapy, immunotherapy and nonviral gene therapy, using our well-established in vitro and PDX models. These studies have led to several FDA-approved drugs for the treatment of leukemia patients.

Lab Information

Terry Fox Laboratory, British Columbia Cancer Agency

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

Basic and Translational Leukemia Research 0 Gene Therapies 0 Oncology 0 Leukemia Stem Cells 0 Drug Resistance of Leukemic Cells 0

More

  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (0)


This guy hasn’t posted anything yet.

Hot Posts for You

Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host. It is a key parameter to evaluate COVID-19 vaccine efficacy per Guidelines from Development and ...Learn More


This 3D animation shows you how DNA is copied in a cell. It shows how both strands of the DNA helix are unzipped and copied to produce two identical DNA molecules. TranscriptDNA is a molecule made up of two strands twisted around each other in a double helix shape. Each strand is ...Learn More


IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More


"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More


In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More


The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More


This is the first episode of MolecularCloud Pioneer Scientist interview series. In this interview, MolecularCloud talks with Prof. Shuo Huang from Nanjing University about the recent publications of Dr. Huang’s team and the future prospect of biological nanopore technology. The ...Learn More


The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More


The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More


  1. Lai D, Chen M, Su J, et al. PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia. Sci Transl Med. 2018;10(427):eaan8735. doi:10.1126/scitranslmed.aan8735

  2. Chen M, Turhan AG, Ding H, Lin Q, Meng K, Jiang X. Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex. Oncotarget. 2017;8(27):43662-43677. doi:10.18632/oncotarget.18216

  3. Rothe K, Babaian A, Nakamichi N, et al. Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors. Cell Stem Cell. 2020;27(1):110-124.e9. doi:10.1016/j.stem.2020.04.005

  4. Li X, Zhang B, Yan C, et al. A fast and specific fluorescent probe for thioredoxin reductase that works via disulphide bond cleavage. Nat Commun. 2019;10(1):2745. Published 2019 Jun 21. doi:10.1038/s41467-019-10807-8

  5. Remant KC, Thapa B, Valencia-Serna J, et al. Cholesterol grafted cationic lipopolymers: Potential siRNA carriers for selective chronic myeloid leukemia therapy. J Biomed Mater Res A. 2020;108(3):565-580. doi:10.1002/jbm.a.36837


This guy hasn’t plasmids anything yet.

Hot plasmids


This guy has no following anyone.

Popular Cloud Scientists


This guy has no follower now.

Cloud Scientists

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2025 MolecularCloud